HRTX Q3 2017 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+1196.8% YoY

Gross Profit

$8M87.7% margin

Operating Income

-$41M-482.0% margin

Net Income

-$42M-488.4% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$118M

Total Liabilities

$78M

Stockholders' Equity

$40M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$661,000	+1196.8%
Gross Profit	$8M	-$304,000	+2574.0%
Operating Income	-$41M	-$48M	+13.4%
Net Income	-$42M	-$49M	+13.7%